Telix Pharmaceuticals Limited
Important Dates
Telix Pharmaceuticals Limited's next confirmed earnings release is scheduled for February 19, 2027.
| Earnings Date | 2/19/2027 |
Share Statistics
As of December 31, 2023, Telix Pharmaceuticals Limited has 323.73M shares outstanding.
| Shares Outstanding | 323.73M |
Financial Position
As of December 31, 2023, Telix Pharmaceuticals Limited maintains a current ratio of 1.42, meaning it holds 1.4x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 1.42 |
| Quick Ratio | 1.20 |
| Debt / Equity | 11.95 |
Financial Efficiency
These figures cover the twelve months ended December 31, 2023.
| Employee Count | 262.25 |
Stock Price Statistics
EURAs of the close on October 22, 2026, Telix Pharmaceuticals Limited's stock has declined approximately 8.02% over the past 52 weeks. The 50-day moving average sits at 9.93, while the 200-day moving average is 8.53.
| 52-Week Price Change | -8.02% |
| 50-Day Moving Average | 9.93 |
| 200-Day Moving Average | 8.53 |
Balance Sheet
EURAs of December 31, 2023, Telix Pharmaceuticals Limited holds 52.03M in cash and equivalents against 7.57M in total debt, resulting in a net debt position of -47.95M. Total book value stands at 63.35M, with working capital of 29.21M providing operational flexibility.
| Cash & Cash Equivalents | 52.03M |
| Total Debt | 7.57M |
| Net Debt | -47.95M |
| Equity (Book Value) | 63.35M |
| Book Value Per Share | 0.20 |
| Working Capital | 29.21M |